Genetic Leap and Eli Lilly Ink $409M AI-driven deal to revolutionize RNA-based therapies

New York, September 5, 2024 (PRNewswire) -- Genetic Leap and Eli Lilly have teamed up to advance genetic medicine using AI-powered RNA-targeting technology. This collaboration aims to create new oligonucleotide drugs for diseases that have been hard to address with traditional therapies. The partnership could net Genetic Leap up to $409 million and accelerate breakthroughs in therapeutic development.

Read full article here.